Reversible Focal Hepatic Steatosis in Type 1 Diabetic Patients Treated With Intraperitoneal Insulin Implantable Pump Therapy
- Laurent Meyer, MD12,
- Jeremy Jeantroux, MD34,
- Jean Pierre Riveline, MD5,
- François Moreau, MD12,
- Sophie Boivin, MD12,
- Thomas Moser, MD34,
- Michel Pinget, MD12 and
- Nathalie Jeandidier, MD, PHD12
- 1Centre Hospitalier Régional Universitaire de Strasbourg, Service d'Endocrinologie, Diabète et Maladies Métaboliques, Hôpital Civil, Strasbourg, France
- 2Université Louis Pasteur, Faculté de Médecine, Strasbourg, France
- 3Centre Hospitalier Régional Universitaire de Strasbourg, Service de Radiologie Hôpital Civil, Strasbourg, France
- 4Université Louis Pasteur, Faculté de Médecine, Strasbourg, France
- 5Department of Diabetology, Hospital of Corbeil Essonnes, Corbeil Essonnes, France
- Corresponding author: Laurent Meyer, MD, Service d’Endocrinologie, Diabète et Maladies Métaboliques, Pavillon Leriche, 1 Place de l'Hôpital, 67000, Strasbourg, France. E-mail: laurent.meyer{at}chru-strasbourg.fr
Intraperitoneal insulin infusion (IPII) using implantable devices is used in treatment of hypoglycemia-prone diabetes. A 35-year-old type 1 diabetic woman had been treated with IPII for 3 years when a metabolic degradation occurred. A catheter tip obstruction wassuspected. An enhanced computed tomography (CT) scan was performed showing a subcapsular hypoattenuating region in the left lobe of the liver, consistent with focal steatosis. The catheter tip, surrounded by a thickening of tissue, stuck to the …
